PPD Selected as Exclusive Partner by DiabetesAmerica
Wilmington, NC
PPD, Inc. announced it has entered into an exclusive alliance with DiabetesAmerica, a provider of comprehensive diabetes care services based in Houston, Texas. Under the agreement, PPD will provide clinical research training and support to more than 20 clinical trial investigators who will conduct Type 1 and Type 2 diabetes clinical trials from DiabetesAmerica's 17 centers across Texas and Arizona.
In return, DiabetesAmerica will work exclusively with PPD to provide clinical research services for endocrine and metabolic disease development programs over a minimum of three years. The agreement expands PPD's ability to recruit for diabetes-related clinical trials through the use of DiabetesAmerica's 16,000-plus patient database.
"Diabetes is a disease with serious complications that affects more than 23 million Americans," said Mike Wilkinson, executive vice president of clinical development at PPD. "We are pleased to assist these physicians in bringing cutting-edge diabetes treatments to their patients through training and support. In addition, DiabetesAmerica's patient database expands our ability to offer clinical trial options to a broader population of people living with this increasingly common disease."
"DiabetesAmerica is committed to delivering the latest treatments in diabetes care to our patients," said Rosemary Mazanet, MD, PhD, and CEO of DiabetesAmerica. "Our alliance with PPD will help ensure our physicians are fully trained on managing drug development programs so we can continue to bring complete diabetes care to our patients."
See a free diabetes and obesity podcast series to learn more about clinical trials in these therapeutic areas.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
